Not Yet RecruitingNot Applicable

Fecal Calprotectin in Patients Infected with Intestinal Protozoan Infections

Egypt120 participantsStarted 2025-03

Plain-language summary

Calprotectin extracted from stool can be detected easily using ELISA. Numerous studies have shown that fecal calprotectin concentrations demonstrate a good correlation with intestinal inflammation This study aims to detect the relationship between fecal calprotectin and Blastocystis hominis and Entamoeba histolytica infections.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: 120 fecal samples will be collected as the following: * 40 samples from patients complaining of gastrointestinal manifestations and only infected with B.hominis and E.histolytica. * 40 samples from patients complaining of gastrointestinal manifestations without any protozoal infection. * 40 healthy control cross-matched volunteers (without gastrointestinal manifestations, or intestinal parasites). Exclusion Criteria: * persons received antiparasitic drugs or antibiotic 2 weeks before sample collection Patients with mixed intestinal protozoa Patients with intestinal protozoa rather than Entamoeba histolytica and Blastocystis

What they're measuring

Prevalence of Blastocystis and Entamoeba

Timeframe: 2 months

Trial details

NCT IDNCT06890455

SponsorSohag University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-10

Contact for this trial

Youstina Kamel Boles, Demonstrator

+20 12 73435308 youstena.kamel@med.sohag.edu.eg

View on ClinicalTrials.gov More Fecal Calprotectin in Intestinal Protozoa trials